RxDoctor Payments Data

Michael Fastenberg, MD

Dermatology · Smithtown, NYNPI 1073735593

Payments from drug & device makers

$357,233in general payments, 2019–2025

Across 1,803 payments — averaging $198.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$81K
  • Amgen$72K
  • Arcutis Biotherapeutics, Inc.$69K
  • VYNE Pharmaceuticals Inc.$41K
  • Pfizer$23K
  • Verrica Pharmaceuticals Inc.$13K
  • plus $58K from 39 others

What the payments were for

  • Consulting fees$61,62417%
  • Speaking & faculty fees$254,95471%
  • Travel & lodging$1,5060%
  • Food & beverage$38,36311%
  • Education$7850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$357,233 in reported general payments places this provider in the 90th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$500,630
Medicare patients
1,072
Services billed
7,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab15$194,638
Humira PenAdalimumab13$87,225
Dupixent SyringeDupilumab11$40,776
ZoryveRoflumilast19$16,053
Calcipotriene21$9,337
Ketoconazole275$3,804
Clobetasol Propionate52$2,328
Clindamycin Phosphate34$2,014
Halobetasol Propionate22$1,547
Metronidazole36$1,531
Triamcinolone Acetonide133$1,471
Fluorouracil25$1,382
Tretinoin22$988
Fluocinonide11$626
Hydrocortisone52$395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,609$194,63815 claims
Arcutis Biotherapeutics, Inc.Zoryve$68,918$16,05319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,151 dermatology providers in New York.

Other dermatology in Smithtown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →